<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02756689</url>
  </required_header>
  <id_info>
    <org_study_id>F151022005</org_study_id>
    <nct_id>NCT02756689</nct_id>
  </id_info>
  <brief_title>Outpatient Foley For Starting Induction of Labor at TErm</brief_title>
  <acronym>OFFSITE</acronym>
  <official_title>Outpatient Foley for Starting Induction of Labor at Term</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are performing a randomized controlled-trial investigating starting
      cervical ripening in the outpatient setting with a mechanical method, the transcervical Foley
      catheter. This is a pilot study to establish the efficacy of this method in decreasing time
      as in inpatient and evaluate patient satisfaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction of labor is necessary in one-fourth of women and a large proportion requires
      cervical ripening. Cervical ripening is necessary to shorten the time to delivery and
      increases the chances of a vaginal delivery.

      Outpatient cervical ripening is an attractive alternative to women and physicians because of
      the decreased amount of time spent in the hospital and opportunity for patients to be in the
      comforts of their home.

      The investigators will conduct a randomized controlled trial comparing outpatient to
      inpatient cervical ripening using a transcervical Foley catheter. Women will be randomized to
      undergo inpatient or outpatient transcervical Foley catheter cervical ripening beyond their
      39th week of gestation. Women and their infants will be followed until the time of their
      discharge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total time from admission to delivery</measure>
    <time_frame>From baseline to the time of delivery (baseline is from admission).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>At discharge.</time_frame>
    <description>Assessed through surveys using validated surveys (Lady-X, Six Simple Questions, and the Labor Pain Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital duration</measure>
    <time_frame>From baseline to post-delivery date 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of acetaminophen use</measure>
    <time_frame>From placement of Foley bulb to 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of calls to the obstetrical triage unit</measure>
    <time_frame>From placement of Foley bulb to 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of admission prior to the scheduled induction of labor time</measure>
    <time_frame>From placement of Foley bulb to 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of spontaneous rupture of membranes between Foley bulb placement and admission</measure>
    <time_frame>From placement of Foley bulb to 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nonreassuring fetal heart tracings 30-minutes after Foley bulb placement.</measure>
    <time_frame>From placement until 30 minutes.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of time of neuraxial anesthesia use</measure>
    <time_frame>Assessed from baseline to delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of time from rupture of membranes until delivery</measure>
    <time_frame>Assessed from baseline to delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum oxytocin rate</measure>
    <time_frame>Assessed from baseline to delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest maternal intrapartum temperature</measure>
    <time_frame>Assessed from baseline to delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of chorioamnionitis</measure>
    <time_frame>Assessed from baseline to delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of meconium-stained fluid</measure>
    <time_frame>Assessed from baseline to delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of shoulder dystocia</measure>
    <time_frame>Assessed at delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of cesarean delivery</measure>
    <time_frame>Assessed from baseline to delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of operative vaginal delivery</measure>
    <time_frame>Assessed at delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum hemorrhage</measure>
    <time_frame>Assessed at delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of endometritis</measure>
    <time_frame>Assessed from delivery until 30 days post-discharge.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of hospital readmission within 30 days</measure>
    <time_frame>Assessed from time of discharge until 30 days post-discharge.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of 5-minute Apgar &lt; 7</measure>
    <time_frame>Assessed at time of delivery up to 5-minutes post-delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of umbilical artery cord pH &lt; 7.1</measure>
    <time_frame>Assessed at time of delivery up to 5-minutes post-delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of umbilical cord artery base deficit &lt; -12</measure>
    <time_frame>Assessed at time of delivery up to 5-minutes post-delivery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of birth injuries</measure>
    <time_frame>Assessed at time of delivery up to time of neonatal discharge, up to 30 days.</time_frame>
    <description>Cephalohematomas, subgaleal hematomas, fracture of the clavicle, and scalp lacerations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of neonatal intensive care unit admissions</measure>
    <time_frame>Assessed at time of delivery up to time of neonatal discharge, up to 30-days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Inpatient Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Outpatient Group (Intervention)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (treatment arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next morning to be admitted to labor and delivery for oxytocin administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inpatient cervical ripening</intervention_name>
    <description>Subjects will undergo cervical ripening in the inpatient setting.</description>
    <arm_group_label>Inpatient Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Outpatient cervical ripening</intervention_name>
    <description>Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.</description>
    <arm_group_label>Outpatient Group (Intervention)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18

          -  Multiparous

          -  Singleton gestation

          -  Gestational age between 39+0 and 42+0

          -  Vertex presentation

          -  Cervix ≤ 3 cm. If cervix is between 2 and 3 cm dilated, it must be &lt;80% effaced

          -  No prior cesarean section or uterine surgery

          -  Resides within Jefferson County, Alabama.

          -  Access to a telephone

          -  Reliable transportation

        Exclusion Criteria:

          -  Unsuitable for outpatient Foley placement management (IUGR, oligohydramnios, prior
             cesarean delivery, gestational hypertension, preeclampsia, or uncontrolled chronic
             hypertension, complex maternal disease, provider discretion). Any patient with
             pregestational or gestational diabetes on medications will be excluded.

          -  Latex allergy

          -  Contraindication to induction of labor

          -  Evidence of labor

          -  Fetal anomaly or demise

          -  Inability to given consent (non-English speaking, inability to read or write)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Spencer G Kuper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAB, Division of Obstetrics and Gynecology, Department of Maternal-Fetal Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Spencer G Kuper, MD</last_name>
    <phone>205-934-9188</phone>
    <email>sgkuper@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lorie M Harper, MD, MSCI</last_name>
    <phone>205-934-2565</phone>
    <email>lmharper@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spencer G Kuper, MD</last_name>
      <phone>205-934-9188</phone>
      <email>sgkuper@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Spencer G Kuper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorie M Harper, MD, MSCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>WHO Recommendations for Induction of Labour. Geneva: World Health Organization; 2011.</citation>
    <PMID>23586118</PMID>
  </reference>
  <reference>
    <citation>Kelly AJ, Alfirevic Z, Ghosh A. Outpatient versus inpatient induction of labour for improving birth outcomes. Cochrane Database Syst Rev. 2013 Nov 12;(11):CD007372. doi: 10.1002/14651858.CD007372.pub3. Review.</citation>
    <PMID>24222365</PMID>
  </reference>
  <reference>
    <citation>Wing DA. Labor induction with misoprostol. Am J Obstet Gynecol. 1999 Aug;181(2):339-45. Review.</citation>
    <PMID>10454679</PMID>
  </reference>
  <reference>
    <citation>Alfirevic Z, Kelly AJ, Dowswell T. Intravenous oxytocin alone for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003246. doi: 10.1002/14651858.CD003246.pub2. Review.</citation>
    <PMID>19821304</PMID>
  </reference>
  <reference>
    <citation>Jozwiak M, Bloemenkamp KW, Kelly AJ, Mol BW, Irion O, Boulvain M. Mechanical methods for induction of labour. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD001233. doi: 10.1002/14651858.CD001233.pub2. Review.</citation>
    <PMID>22419277</PMID>
  </reference>
  <reference>
    <citation>Farmer KC, Schwartz WJ 3rd, Rayburn WF, Turnbull G. A cost-minimization analysis of intracervical prostaglandin E2 for cervical ripening in an outpatient versus inpatient setting. Clin Ther. 1996 Jul-Aug;18(4):747-56; discussion 702.</citation>
    <PMID>8879901</PMID>
  </reference>
  <reference>
    <citation>Dowswell T, Kelly AJ, Livio S, Norman JE, Alfirevic Z. Different methods for the induction of labour in outpatient settings. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007701. doi: 10.1002/14651858.CD007701.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Sep 13;9:CD007701.</citation>
    <PMID>20687092</PMID>
  </reference>
  <reference>
    <citation>O'Brien JM, Mercer BM, Cleary NT, Sibai BM. Efficacy of outpatient induction with low-dose intravaginal prostaglandin E2: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1995 Dec;173(6):1855-9.</citation>
    <PMID>8610775</PMID>
  </reference>
  <reference>
    <citation>McKenna DS, Costa SW, Samuels P. Prostaglandin E2 cervical ripening without subsequent induction of labor. Obstet Gynecol. 1999 Jul;94(1):11-4.</citation>
    <PMID>10389710</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee on Practice Bulletins -- Obstetrics. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol. 2009 Aug;114(2 Pt 1):386-97. doi: 10.1097/AOG.0b013e3181b48ef5. Review.</citation>
    <PMID>19623003</PMID>
  </reference>
  <reference>
    <citation>Edwards RK, Szychowski JM, Berger JL, Petersen M, Ingersoll M, Bodea-Braescu AV, Lin MG. Foley catheter compared with the controlled-release dinoprostone insert: a randomized controlled trial. Obstet Gynecol. 2014 Jun;123(6):1280-7. doi: 10.1097/AOG.0000000000000238.</citation>
    <PMID>24807327</PMID>
  </reference>
  <reference>
    <citation>Pettker CM, Pocock SB, Smok DP, Lee SM, Devine PC. Transcervical Foley catheter with and without oxytocin for cervical ripening: a randomized controlled trial. Obstet Gynecol. 2008 Jun;111(6):1320-6. doi: 10.1097/AOG.0b013e31817615a0.</citation>
    <PMID>18515515</PMID>
  </reference>
  <reference>
    <citation>Sciscione AC, Bedder CL, Hoffman MK, Ruhstaller K, Shlossman PA. The timing of adverse events with Foley catheter preinduction cervical ripening; implications for outpatient use. Am J Perinatol. 2014 Oct;31(9):781-6. doi: 10.1055/s-0033-1359718. Epub 2013 Dec 17.</citation>
    <PMID>24347259</PMID>
  </reference>
  <reference>
    <citation>Henry A, Madan A, Reid R, Tracy SK, Austin K, Welsh A, Challis D. Outpatient Foley catheter versus inpatient prostaglandin E2 gel for induction of labour: a randomised trial. BMC Pregnancy Childbirth. 2013 Jan 29;13:25. doi: 10.1186/1471-2393-13-25.</citation>
    <PMID>23356673</PMID>
  </reference>
  <reference>
    <citation>McMaster K, Sanchez-Ramos L, Kaunitz AM. Evaluation of a Transcervical Foley Catheter as a Source of Infection: A Systematic Review and Meta-analysis. Obstet Gynecol. 2015 Sep;126(3):539-51. doi: 10.1097/AOG.0000000000001002. Review.</citation>
    <PMID>26244535</PMID>
  </reference>
  <results_reference>
    <citation>Sciscione AC, Muench M, Pollock M, Jenkins TM, Tildon-Burton J, Colmorgen GH. Transcervical Foley catheter for preinduction cervical ripening in an outpatient versus inpatient setting. Obstet Gynecol. 2001 Nov;98(5 Pt 1):751-6.</citation>
    <PMID>11704164</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Spencer G. Kuper</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Mechanical cervical ripening</keyword>
  <keyword>Transcervical catheter</keyword>
  <keyword>Foley catheter for labor induction</keyword>
  <keyword>Cervical ripening</keyword>
  <keyword>Induction of labor</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

